GH
Guardant Health, Inc.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- May 27 Cold Spring Harbor Laboratory v. Guardant Health, Inc.
- Jun 5 Goldman Sachs initiates
- Jun 11 RBC Capital initiates
- Jun 16 TwinStrand Biosciences, Inc. & University of Washington…
- Sep 8 Rothschild & Co initiates
- Sep 16 ▼ 2 insiders sell $212.7K at $174.51
- Sep 28 ▲ Jonathan Jackson bought $15,001 - $50,000, last disclosed Oct 20
- Sep 30 ▲ 4 funds open new positions (13F)
- Oct 14 to Oct 16 ▼ 2 days of insider sells: $30.3K by 2 insiders, avg $163.65
- Oct 23 Roth Capital initiates
- Nov 5 ▲ Guardant Health reported Q3 2026 revenue of $361.0M, up 36% YoY and…
- Nov 5 ▲ Earnings: GH Q3 2026 Earnings: EPS $-0.29 (+10.9% vs est)
Signal stack
Where each data set points today.
- InsidersBEARISH
3 insiders sold $243.0K.
- InstitutionsBULLISH
Q3 2026: 55 added (4 new), 28 trimmed or exited. Largest new: Agf Management $201.8M, Nomura Asset Management $28.8M.
- AnalystsBULLISH
33 of 36 rate it Buy or better. Median target $200.00 (+39%).
- Short sellersCOVERING
Short interest −19.2% to 9.43M shares. 5.4 days to cover, ≈7.0% of shares.
- TrendDOWNTREND
14% below its 50-day average.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| FMR LLC | ADD | $1.3B |
| Invesco Ltd. | TRIM | $530.5M |
| FULLER & THALER ASSET MANAGEMENT, INC. | TRIM | $303.0M |
| Qube Research & Technologies Ltd | DOUBLED | $233.0M |
| UBS Group AG | ADD | $205.0M |
| AGF MANAGEMENT LTD | NEW | $201.8M |
| WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC | TRIM | $167.3M |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | TRIM | $162.7M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
36 analystsPrice is inside the target range. Median implies +39%.Targets as of Nov 17, 2026.
| Date | Firm | Rating |
|---|---|---|
| Nov 10, 2026 | Piper Sandler MAINTAIN | Overweight |
| Oct 27, 2026 | BTIG MAINTAIN | Buy |
| Oct 23, 2026 | Roth Capital INITIATE | Buy |
| Oct 13, 2026 | Morgan Stanley MAINTAIN | Overweight |
| Oct 7, 2026 | Barclays MAINTAIN | Overweight |
| Oct 1, 2026 | Guggenheim MAINTAIN | Buy |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Azar Alex M II Director Nov 12, 2026 | EXERCISE | 138 sh |
PARKS ROBERT Chief Accounting Officer Nov 9, 2026 | AWARD | 18,893 sh |
SAYER KEVIN R Director Nov 9, 2026 | AWARD | 3,149 sh |
MIGNONE ROBERTO Director Oct 21, 2026 | EXERCISE | 264 sh |
Hidalgo Medina Manuel Director Oct 17, 2026 | EXERCISE | 232 sh |
Tariq Musa Director Oct 16, 2026 | SELL | $19.2K |
Tariq Musa Director Oct 15, 2026 | EXERCISE | 250 sh |
Azar Alex M II Director Oct 14, 2026 | SELL | $11.0K |
Earnings setup
EstimatesRevision history: 🔒 Fresh data, subscribers only
| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | 🔒 Fresh data, subscribers only | |||
| Next Q | 🔒 Fresh data, subscribers only | |||
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Washington
Short side
FINRA· Oct 30, 2026SecBot reports
38 filings · 2 bullish · 5 bearish · 31 neutral- NEUTRAL 144Nov 16, 2026
Two Guardant Health directors, Alex M. Azar II and Tariq Musa, each filed Form 144 notices on November 16, 2026, signaling intent to sell shares. Azar plans to sell 207 shares (~$30,959) and Musa 116 shares (~$17,349), both from restricted stock lapses.
🔒 Fresh report (last 24h), subscribers only
- NEUTRAL 3Nov 12, 2026
Kevin R. Sayer filed a Form 3 initial statement of beneficial ownership with the SEC, reporting…
This is a routine initial ownership filing with no trading activity. Monitor future Form 4 filings for any insider transactions by Kevin Sayer.
- NEUTRAL 3Nov 12, 2026
Robert Parks filed a Form 3 initial statement of beneficial ownership with the SEC, reporting zero…
Monitor future Form 4 filings by Parks for any insider transactions that may signal management's view of the stock. This initial filing is purely administrative.
- BULLISH 8-KNov 5, 2026
Guardant Health reported Q3 2026 revenue of $361.0M, up 36% YoY and above the $350.6M consensus…
The revenue beat and raised guidance confirm strong commercial momentum, especially in Shield screening. The GAAP EPS miss is secondary given the non-cash stock-based compensation. Watch for Shield…
All GH filing & press-release reports (38)
- 144 reportNov 16, 2026
- 3 reportNov 12, 2026
- 3 reportNov 12, 2026
- 8-K reportNov 5, 2026
- SC 13G reportNov 5, 2026
- 8-K reportNov 3, 2026
- 8-K reportNov 3, 2026
- INST-CLUSTER reportOct 21, 2026
- 144 reportOct 14, 2026
- CLUSTER reportSep 17, 2026
- CLUSTER reportSep 17, 2026
- CLUSTER reportSep 17, 2026
- CLUSTER reportAug 24, 2026
- CLUSTER reportAug 13, 2026
- CLUSTER reportAug 13, 2026
- CLUSTER reportAug 11, 2026
- CLUSTER reportAug 11, 2026
- CLUSTER reportAug 6, 2026
- S-3ASR reportJul 30, 2026
- CLUSTER reportJun 30, 2026
- 144 reportJun 22, 2026
- COURT-RULING reportJun 16, 2026
- CLUSTER reportJun 15, 2026
- CLUSTER reportJun 12, 2026
- CLUSTER reportJun 5, 2026
- 144 reportMay 22, 2026
- CLUSTER reportJun 4, 2026
- CLUSTER reportMay 29, 2026
- CLUSTER reportMay 29, 2026
- CLUSTER reportMay 28, 2026
- COURT-RULING reportMay 27, 2026
- CLUSTER reportMay 26, 2026
- CLUSTER reportMay 22, 2026
- CLUSTER reportMay 22, 2026
- 144 reportMay 12, 2026
- DEFA14A reportApr 28, 2026
- 8-K reportApr 27, 2026
- CLUSTER reportMar 16, 2026